Hill Emily Luisa sold $132K of REPL

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.

Replimune Group (REPL) reported a Q1 2026 net loss of $69.77M and appointed Michelle DiNapoli as CCO. Its stock surged 62.89% in 1 month and 236.17% in 90 days, reaching $15.80. The company trades at a P/B ratio of 14.1x, significantly higher than peers, raising valuation concerns despite a DCF model suggesting higher potential value.

The Law Offices of Frank R. Cruz invites Replimune Group (REPL) investors who suffered losses to join a securities fraud class action lawsuit. The complaint alleges misstatements and omissions about the company's business and prospects between October 20, 2025, and April 10, 2026, including FDA concerns and data submission issues. Investors have until October 5, 2026, to participate.

Replimune Group reported a reduced net loss of $69.77M in Q1 2026, appointed Michelle DiNapoli as CCO, and raised $150M via equity offering. The company's investment narrative focuses on its newly approved oncolytic therapy, TUDRIQEV, and its commercial launch potential. Analysts note the trade-offs between financing, dilution, and execution risks.

Replimune Group (REPL) shares dropped 60% after the FDA rejected its melanoma treatment, RP1, for the second time. The company may scale back operations. Jefferies cut its price target to $2 from $13, and JPMorgan downgraded the stock to 'Underweight'.

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Replimune Group, Inc. (NASDAQ:REPL) and certain officers, alleging securities law violations. The lawsuit covers investors who acquired Replimune securities between October 20, 2025, and April 10, 2026. The complaint claims Replimune made false statements and omitted key information regarding FDA concerns and clinical trial data. Investors have until October 5, 2026, to request lead plaintiff status.